Wockhardt Limited (BOM:532300)

Market Cap	266.51B
Revenue (ttm)	30.12B
Net Income (ttm)	-470.00M
Shares Out	n/a
EPS (ttm)	-3.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	298,672
Average Volume	101,355
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	630.10 - 1,870.00
Beta	n/a
RSI	53.80
Earnings Date	Aug 8, 2025

About Wockhardt

Wockhardt Limited, a pharmaceutical and biotech company, manufactures and trades pharmaceuticals, medicinal, botanical, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. The company develops qualified infectious diseases products comprising WCK5222, which is in phase 3 clinical trial for the treatment of sepsis and hospital/ventilator associated pneumonia; WCK 4282, which is in phase 3 clinical trial for ESBL infections; WCK 6777, which is phase 1 to treat gram nega...

• Industry: Pharmaceutical Preparations
• Founded: 1967
• Employees: 2,386
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532300

Financial Performance

In 2024, Wockhardt's revenue was 30.12 billion, an increase of 6.43% compared to the previous year's 28.30 billion. Losses were -470.00 million, -89.85% less than in 2023.